Asset Management One Co. Ltd. Buys 3,057 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Asset Management One Co. Ltd. lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.1% in the fourth quarter, HoldingsChannel reports. The fund owned 52,844 shares of the company’s stock after acquiring an additional 3,057 shares during the period. Asset Management One Co. Ltd.’s holdings in IDEXX Laboratories were worth $21,927,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IDXX. International Assets Investment Management LLC boosted its position in shares of IDEXX Laboratories by 52,746.0% in the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock worth $2,669,890,000 after purchasing an additional 527,460 shares during the period. Assenagon Asset Management S.A. lifted its stake in shares of IDEXX Laboratories by 265.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock valued at $179,867,000 after buying an additional 316,048 shares in the last quarter. Seilern Investment Management Ltd bought a new position in IDEXX Laboratories in the 4th quarter worth $113,104,000. Worldquant Millennium Advisors LLC increased its stake in IDEXX Laboratories by 230.1% in the 3rd quarter. Worldquant Millennium Advisors LLC now owns 110,196 shares of the company’s stock worth $55,673,000 after buying an additional 76,809 shares in the last quarter. Finally, Thrivent Financial for Lutherans raised its holdings in IDEXX Laboratories by 150.6% during the third quarter. Thrivent Financial for Lutherans now owns 108,258 shares of the company’s stock valued at $54,693,000 after acquiring an additional 65,050 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Bank of America lifted their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Piper Sandler upped their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Barclays lifted their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Finally, Morgan Stanley dropped their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

Insider Activity

In other news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 13,330 shares of company stock valued at $6,161,276 in the last ninety days. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Down 3.3 %

IDXX opened at $444.53 on Friday. The stock has a 50-day moving average of $430.95 and a 200 day moving average of $453.11. The company has a current ratio of 1.31, a quick ratio of 1.03 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The firm has a market cap of $36.40 billion, a P/E ratio of 41.66, a P/E/G ratio of 3.47 and a beta of 1.37.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.